SecBot SecBot

CYCN

Korsana Biosciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. MA· CIK 0001755237 Biotech & Drug Discovery
Former ticker of Korsana Biosciences, Inc. · KRSA stock page →
—
Market cap
$15.7M
Nano cap
Median target
$56.00
range $56.00–56.00
Short interest
18.1K
≈0.4% of shares · −65.5%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 6 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/6
Strongest MIXED Korsana Biosciences (formerly Cyclerion Therapeutics) completed its reverse merger with Korsana on September…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 3 added (0 new), 1 trimmed or exited.

  • Short sellersCOVERING

    Short interest −65.5% to 18.1K shares. 1.0 days to cover, ≈0.4% of shares.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
FMR LLCDOUBLED649,547$2.2M
CITADEL ADVISORS LLCDOUBLED59,795$202.7K
GEODE CAPITAL MANAGEMENT, LLCTRIM45,850$155.5K
VANGUARD CAPITAL MANAGEMENT LLCADD30,915$104.8K
GEODE CAPITAL MANAGEMENT, LLCADD84,550$129.8K
UBS Group AGDOUBLED3,391$5.3K
CITIGROUP INCNEAR_EXIT89$137.00
TWO SIGMA INVESTMENTS, LPDOUBLED41,555$52.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 9, 2026
Listing
Delisted: CYCN — removed from the Nasdaq symbol directory
Cyclerion Therapeutics, Inc. - Common Stock
Sep 9, 2026
Trading halt
Halt Resumed: CYCN — trading resumed after D (Security Deletion)
Halted 2026-09-08T23:50:00.000Z | Resumed 2026-09-09T04:00:01.000Z
Sep 8, 2026
Trading halt
Trading Halt: CYCN — T1 (News Pending)
Cyclerion Therapeutics Cmn Stk | Market: NASDAQ | Code: T1 — News Pending
Sep 8, 2026
Trading halt
Trading Halt: CYCN — D (Security Deletion)
Cyclerion Therapeutics Cmn Stk | Market: NASDAQ | Code: D — Security Deletion
Sep 8, 2026
Trading halt
Halt Resumed: CYCN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-08T13:32:31.000Z | Resumed 2026-09-08T13:42:31.000Z

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 14, 2026
CHICKO RHONDA M.
Chief Financial Officer
EXERCISE$58.9K
Aug 14, 2026
Graul Regina Margaret
See Remarks
EXERCISE$184.3K
Aug 14, 2026
Graul Regina Margaret
See Remarks
TAX W/H$184.3K
Jul 16, 2026
Hecht Peter M
Director
CONVERT351,037 sh
Jul 16, 2026
Hecht Peter M
Director
CONVERT351,037 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Aug 31, 2026
18,067
shares short
-65.5%
vs prior settlement
1.0
days to cover
≈0.4%
of shares outstanding
Trading halts
Sep 8, 2026DeletionResumed
Sep 8, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 7, 2026 SEC
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 3,144,797 shares of Korsana…
SC 13G/A — Impact 3/10
Sep 11, 2026 SEC
Korsana Biosciences (formerly Cyclerion Therapeutics) completed its reverse merger with Korsana on September 8, 2026…
8-K — Impact 7/10
Sep 10, 2026 SEC
CEO Jonathan Violin and director Heidi Henson filed initial beneficial ownership statements (Form 3) following the…
3 — Impact 3/10
Sep 9, 2026 Listing status
Delisted: CYCN — removed from the Nasdaq symbol directory
Cyclerion Therapeutics, Inc. - Common Stock
Aug 14, 2026 Insider
CHICKO RHONDA M. acquired via exercise 25,000 shares
Chief Financial Officer @ $2.36 ($58.9K)
Aug 14, 2026 Insider
Graul Regina Margaret acquired via exercise 55,849 shares
See Remarks @ $3.30 ($184.3K)
Aug 14, 2026 Insider
Graul Regina Margaret surrendered for taxes 48,629 shares
See Remarks @ $3.79 ($184.3K)
Aug 7, 2026 Event
CAVHANZA
WARNING: QT PROLONGATION and SUDDEN DEATHS Nilotinib prolongs the QT interval. Prior to CAVHANZA adm

SecBot reports

11 filings · 1 bullish · 1 bearish · 4 mixed · 5 neutral
All CYCN filing & press-release reports (11)